A research team made a pivotal discovery in the field of cancer immunotherapy. The team identified a specific population of immune cells that play a critical role in successful treatment of relapsed ...

Immune cells in the bone marrow microenvironment of AML patients are key in distinguishing a response to immunotherapy.

Mikkael A. Sekeres, MD, Sylvester Comprehensive Cancer Center, discusses the potential benefits of treosulfan, a newly ...

Mixed lineage leukemia (MLL)-fusion proteins can induce acute myeloid leukemias (AMLs) from either hematopoietic stem cells (HSCs) or granulocyte–macrophage progenitors (GMPs), but it remains ...

In this study, 1557 patients with untreated acute myeloid leukemia were given induction chemotherapy. Consolidation therapy, including the use of stem cell transplant, was based on a risk-adapted ...

Such an activated T cell might encounter an AML blast presenting the same peptide ... cell epitope peptide derived from a LAA. AML: Acute myeloid leukemia; CTL: Cytotoxic T lymphocyte; FasL ...

Dana-Farber Cancer Institute researchers have identified factors that determine whether donor lymphocyte infusion (DLI), a standard therapy for patients with acute myeloid leukemia (AML) who have ...

Patients with acute myeloid leukemia who relapse after stem cell transplantation have just a small chance of survival: doctors can give them additional donor T cells to fight the cancer, but only ...

Dana-Farber Cancer Institute researchers have identified factors that determine whether donor lymphocyte infusion (DLI), a standard therapy for patients with acute myeloid leukemia (AML) who have ...

Aug. 21, 2024 — An international team of scientists has uncovered a mechanism by which acute myeloid leukemia (AML) cells sustain their growth. AML cells prevent the synthesis of proteins that ...

A research team from Columbia Engineering and the Irving Institute for Cancer Dynamics achieved a significant finding in ...